WO2006086992A3 - Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands - Google Patents
Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands Download PDFInfo
- Publication number
- WO2006086992A3 WO2006086992A3 PCT/DK2006/000097 DK2006000097W WO2006086992A3 WO 2006086992 A3 WO2006086992 A3 WO 2006086992A3 DK 2006000097 W DK2006000097 W DK 2006000097W WO 2006086992 A3 WO2006086992 A3 WO 2006086992A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- wound healing
- drug delivery
- delivery systems
- phqspholipase
- therapeutic uses
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention describes a lipid based prodrug and drug delivery system that can be used for treatment or alleviation of disorders that are associated with or resulting from increased levels of secretory phospholipase A2 (PLA2) in the diseased or injured tissue. In particular, the lipid based delivery systems are useful for administration of lipid prodrugs of lysophosphatidic acid (LPA) bioactive analogs, which are known to be potent biological mediators with e.g. growth stimulating and wound healing activities.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200500255 | 2005-02-18 | ||
DKPA200500255 | 2005-02-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006086992A2 WO2006086992A2 (en) | 2006-08-24 |
WO2006086992A3 true WO2006086992A3 (en) | 2007-03-01 |
Family
ID=36916811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2006/000097 WO2006086992A2 (en) | 2005-02-18 | 2006-02-17 | Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006086992A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105434354A (en) * | 2009-06-03 | 2016-03-30 | 斯昆申技术控股有限责任公司 | Formulations for the treatment of deep tissue pain |
JP2013502436A (en) | 2009-08-21 | 2013-01-24 | ターゲッティド デリバリー テクノロジーズ リミテッド | Vesicular preparation |
GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
CA2946275A1 (en) * | 2014-04-04 | 2015-10-08 | Osaka University | Drug delivery enhancer comprising substance for activating lysophospholipid receptors |
WO2017001625A1 (en) | 2015-06-30 | 2017-01-05 | Sequessome Technology Holdings Limited | Multiphasic compositions |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986000309A1 (en) * | 1984-06-21 | 1986-01-16 | Health Research Inc. | Thiophospholipid conjugates of antitumor agents |
WO1999065466A1 (en) * | 1998-06-18 | 1999-12-23 | Duke University | Temperature-sensitive liposomal formulation |
US6165501A (en) * | 1995-12-11 | 2000-12-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiation-protective phospholipid and method |
WO2001058910A2 (en) * | 2000-02-10 | 2001-08-16 | Liplasome Pharma A/S | Lipid-based drug delivery systems |
US20030170297A1 (en) * | 2000-04-12 | 2003-09-11 | Kent Jorgensen | Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin |
WO2004000854A1 (en) * | 2002-06-20 | 2003-12-31 | Ic Vec Limited | Sulfur-containing phospholipid derivatives |
-
2006
- 2006-02-17 WO PCT/DK2006/000097 patent/WO2006086992A2/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986000309A1 (en) * | 1984-06-21 | 1986-01-16 | Health Research Inc. | Thiophospholipid conjugates of antitumor agents |
US6165501A (en) * | 1995-12-11 | 2000-12-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiation-protective phospholipid and method |
WO1999065466A1 (en) * | 1998-06-18 | 1999-12-23 | Duke University | Temperature-sensitive liposomal formulation |
WO2001058910A2 (en) * | 2000-02-10 | 2001-08-16 | Liplasome Pharma A/S | Lipid-based drug delivery systems |
US20030170297A1 (en) * | 2000-04-12 | 2003-09-11 | Kent Jorgensen | Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin |
WO2004000854A1 (en) * | 2002-06-20 | 2003-12-31 | Ic Vec Limited | Sulfur-containing phospholipid derivatives |
Non-Patent Citations (2)
Title |
---|
HRISTOVA ET AL: "Effect of bilayer composition on the phase behavior of liposomal suspensions containing poly(ethylene glycol) lipids", MACROMOLECULES, ACS, WASHINGTON, DC, US, vol. 28, 1995, pages 7693 - 7699, XP002120858, ISSN: 0024-9297 * |
JORGENSEN KENT ET AL: "Interaction of a lipid-membrane destabilizing enzyme with PEG-liposomes", INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 183, no. 1, 10 June 1999 (1999-06-10), pages 21 - 24, XP002404579, ISSN: 0378-5173 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006086992A2 (en) | 2006-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007084247A3 (en) | Stable therapeutic formulations | |
BRPI0707235B8 (en) | sublingual fentanyl formulation without propellant, and, unit dose device for sublingual administration of a sublingual fentanyl formulation | |
EP2963031A3 (en) | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same | |
SG11201808167VA (en) | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | |
WO2011127064A3 (en) | Sustained-release reservoir implants for intracameral drug delivery | |
WO2008079404A3 (en) | Pharmaceutical compositions for treatment of parkinson's disease and related disorders | |
NZ591810A (en) | Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid | |
EA200970287A1 (en) | METHODS, COMPOUNDS, COMPOSITIONS AND MEDIA SUITABLE FOR DELIVERY OF 3-AMINO-1-PROPANSULPHONE ACID | |
NO20084199L (en) | Modified release formulations and methods for treating inflammatory bowel disease | |
WO2006048017A8 (en) | Lipid-based drug delivery systems containing unnatural phospholipase a2 degradable lipid derivatives and the therapeutic uses thereof | |
UY28837A1 (en) | OXADIAZOLONAS PROCEDURES FOR PREPARATION AND USE AS PHARMACEUTICAL PRODUCTS. | |
MX2009004561A (en) | Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain. | |
EP2386299A3 (en) | 1-Amino-Alkylcyclohexane derivatives for the treatment of cochlear tinnitus | |
WO2010093925A3 (en) | Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease | |
EP4218823A3 (en) | Novel polymeric hgh prodrugs | |
WO2008097924A3 (en) | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders | |
WO2006086992A3 (en) | Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands | |
HK1110221A1 (en) | Use of prodrugs for ocular intravitreous administration | |
MX2012009079A (en) | Extended release formulations of rasagiline and uses thereof. | |
TW200731975A (en) | Novel combinations of medicaments for the treatment of respiratory diseases | |
BRPI0417932A (en) | fat accumulation drug lipolysis | |
WO2011151722A3 (en) | Methods and compositions for oral pharmaceutical therapy | |
UY28209A1 (en) | DERIVATIVES OF AMINO ACIDS WITH CYCLLOQUAL, PROCEDURE FOR PREPARATION AND USE AS A MEDICINAL PRODUCT. | |
WO2001058910A3 (en) | Lipid-based drug delivery systems | |
WO2007124358A3 (en) | Pharmaceutical formulations for iontophoretic drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06706068 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06706068 Country of ref document: EP Kind code of ref document: A2 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 6706068 Country of ref document: EP |